| Name | Title | Contact Details |
|---|
MIDi is a Springfield, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people.
Akari Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5). Its lead drug, Covers...
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.